[3] Next-Generation Dual and Multi-Targeted Therapies on the Rise Amycretin: A Promising Dual GLP-1/Amylin Receptor Agonist Also making headlines at ADA 2025 was Amycretin (NNC0487-0111), a novel, unimolecular GLP-1 and amylin receptor agonist under development by Novo Nordisk
Furthermore, recent findings reveal that alterations in BBB and its transporters affect the entry of therapeutic drugs designed to treat neurodegenerative diseases (Carvey et al., 2009)
If exposed to temperatures above 30C heat exposure compromises medication integrity in ways that cannot be reversed
Existing research shows that menstrual changes (like heavier bleeding) can increase iron loss, which plays an important role in transporting oxygen and energy production
In March, the Group Insurance Commission, for example, approved average premium increases of 7.5 percent for thousands of public employees for fiscal year 2027
We are a leading wellness clinic serving the greater Los Angeles and Orange County areas
